Angiotensin Converting Enzyme (ACE) Inhibitors

Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications

Volumn , Issue , 2009, Pages 749-787

  Cámara Artigas, Ana ^a   Jara Pérez, Vicente ^a   Andújar Sánchez, Montserrat ^a  

^a UNIVERSITY OF ALMERÍA   (Spain)

Author keywords

ACE structures and chloride site presence; Drug design studies of other zinc containing enzymes; Kinetic and molecular basis of ACE inhibition

Indexed keywords

EID: 84889289709     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470508169.ch32     Document Type: Chapter

References (158)

1. Staessen, J. A.;Wang, J.; Bianchi, G.; Birkenhager,W.H. Essential hypertension. Lancet 2003, 361, 1629-1641.
2. Small, R. Antihypertensive drugs. Anaesth Intensive Care Med. 2006, 7, 298-302.
3. Black, J.W.; Stephenson, J. S. Pharmacology of a newadrenergic beta-receptor-blocking compound (Nethalide). Lancet 1962, 2, 311-314.
4. Cushman, D. W.; Ondetti, M. A. Design of angiotensin converting enzyme inhibitors. Nat. Med. 1999, 5, 1110-1113.
5. Skeggs, L. T.; Kahn, J. R.; Shumway, N. P. The preparation and function of the hypertensin-converting enzyme. J. Exp. Med. 1956, 103, 295-299.
6. Lipscomb, W. N.; Reeke, G. N., Jr.; Hartsuck, J. A.; Quiocho, F. A.; Bethge, P. H. The structure of carboxypeptidase A. 8. Atomic interpretation at 0.2 nm resolution, a new study of the complex of glycyl-L-tyrosine with CPA, and mechanistic deductions. Philos. Trans. R. Soc. Lond. B Biol. Sci. 1970, 257, 177-214.
7. Greene, L. J.; Camargo, A. C.; Krieger, E. M.; Stewart, J. M.; Ferreira, S. H. Inhibition of the conversion of angiotensin I to II and potentiation of bradykinin by small peptides present in Bothrops jararaca venom. Circ. Res. 1972, 31 (Suppl. 2), 62-71.
8. Monzingo, A. F.; Matthews, B. W. Structure of a mercaptan-thermolysin complex illustrates mode of inhibition of zinc proteases by substrate-analogue mercaptans. Biochemistry 1982, 21, 3390-3394.
9. Patchett, A. A.; Cordes, E. H. The design and properties of N-carboxyalkyldipeptide inhibitors of angiotensin-converting enzyme. Adv. Enzymol. Relat. Areas Mol. Biol. 1985, 57, 1-84.
10. Wong, J.; Patel, R. A.; Kowey, P. R. The clinical use of angiotensin-converting enzyme inhibitors. Prog. Cardiovasc. Dis. 2004, 47, 116-130.
11. Chobanian, A. V.; Bakris, G. L.; Black, H. R.; Cushman, W. C.; Green, L. A.;et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289, 2560-2572.
12. Adam, A.; Cugno, M.; Molinaro, G.; Perez, M.; Lepage, Y.;et al. Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet 2002, 359, 2088-2089.
13. Bicket, D. P. UsingACE inhibitors appropriately. Am. Fam. Physician 2002, 66, 461-468.
14. Corvol, P.; Eyries, M.; Soubrier, F. Peptidyl-dipeptidase A/angiotensin I-converting enzyme. Handbook of Proteolytic Enzymes, Barrett, A. J.; Rawlings, N. D.; Woessner, J. F., eds. 2nd ed.; Academic Press: San Diego, 2004; pp 332-346.
15. Riordan, J. F. Angiotensin-I-converting enzyme and its relatives. Genome Biol. 2003, 4, 225.
16. Acharya, K. R.; Sturrock, E. D.; Riordan, J. F.; Ehlers, M. R. Ace revisited: a new target for structure-based drug design. Nat. Rev. Drug Discov. 2003, 2, 891-902.
17. Sleight, P. The role of angiotensin-converting enzyme inhibitors in the treatment of hypertension. Curr. Cardiol. Rep. 2001, 3, 511-518.
18. Menard, J.; Patchett, A. A. Angiotensin-converting enzyme inhibitors. Adv. Protein Chem. 2001, 56, 13-75.
19. Jackson, B.; Mendelsohn, F. A.; Johnston, C. I. Angiotensin-converting enzyme inhibition: prospects for the future. J. Cardiovasc. Pharmacol. 1991, 18 (Suppl. 7), S4-S8.
20. Matsusaka, T.; Ichikawa, I. Biological functions of angiotensin and its receptors. Annu. Rev. Physiol. 1997, 59, 395-412.
21. Antonaccio, M. J. Angiotensin converting enzyme (ACE) inhibitors. Annu. Rev. Pharmacol. Toxicol. 1982, 22, 57-87.
22. Erdos, E. G. Angiotensin I converting enzyme and the changes in our concepts through the years. Lewis K. Dahl memorial lecture. Hypertension 1990, 16, 363-370.
23. Baudin, B. New aspects on angiotensin-converting enzyme: from gene to disease. Clin. Chem. Lab. Med. 2002, 40, 256-265.
24. Corvol, P. ACE sets up fertilization. Nat. Med. 2005, 11, 118-119.
25. Fuchs, S.; Frenzel, K.; Hubert, C.; Lyng, R.; Muller, L.; et al. Male fertility is dependent on dipeptidase activity of testis ACE. Nat. Med. 2005, 11, 1140-1142, author reply 1142-1143.
26. Erdos, E. G.; Yang, H. Y. An enzyme in microsomal fraction of kidney that inactivates bradykinin. Life Sci. 1967, 6, 569-574.
27. Soubrier, F.; Alhenc-Gelas, F.; Hubert, C.; Allegrini, J.; John, M.; et al. Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc. Natl. Acad. Sci. USA 1988, 85, 9386-9390.
28. Lanzillo, J. J.; Stevens, J.; Dasarathy, Y.; Yotsumoto, H.; Fanburg, B. L. Angiotensinconverting enzyme from human tissues. Physicochemical, catalytic, and immunological properties. J. Biol. Chem. 1985, 260, 14938-14944.
29. Hubert, C.; Houot, A. M.; Corvol, P.; Soubrier, F. Structure of the angiotensin Iconverting enzyme gene. Two alternate promoters correspond to evolutionary steps of a duplicated gene. J. Biol. Chem. 1991, 266, 15377-15383.
30. Langford, K. G.; Shai, S.Y.;Howard, T. E.;Kovac, M. J.;Overbeek, P. A.; et al. Transgenic mice demonstrate a testis-specific promoter for angiotensin-converting enzyme. J. Biol. Chem. 1991, 266, 15559-15562.
31. Hooper, N. M.; Turner, A. J.; Isolation of two differentially glycosylated forms of peptidyl-dipeptidase A (angiotensin converting enzyme) from pig brain: a re-evaluation of their role in neuropeptide metabolism. Biochem. J. 1987, 241, 625-633.
32. Wei, L.; Alhenc-Gelas, F.; Corvol, P.; Clauser, E. The two homologous domains of human angiotensin I-converting enzyme are both catalytically active. J. Biol. Chem. 1991, 266, 9002-9008.
33. Parvathy, S.; Oppong, S.Y.;Karran, E. H.; Buckle, D.R.; Turner,A. J.; et al. Angiotensinconverting enzyme secretase is inhibited by zincmetalloprotease inhibitors and requires its substrate to be inserted in a lipid bilayer. Biochem. J. 1997, 327 (Part 1), 37-43.
34. Oppong, S. Y.; Hooper, N. M. Characterization of a secretase activity which releases angiotensin-converting enzyme from the membrane. Biochem. J. 1993, 292 (Part 2), 597-603.
35. Woodman, Z. L.; Oppong, S.Y.;Cook, S.; Hooper, N.M.; Schwager, S. L.; et al. Shedding of somatic angiotensin-converting enzyme (ACE) is inefficient compared with testis ACE despite cleavage at identical stalk sites. Biochem. J. 2000, 347 (Part 3), 711-718.
36. Beldent, V.; Michaud, A.; Bonnefoy, C.; Chauvet, M. T.; Corvol, P. Cell surface localization of proteolysis of human endothelial angiotensin I-converting enzyme. Effect of the amino-terminal domain in the solubilization process. J. Biol. Chem. 1995, 270, 28962-28969.
37. Woodman, Z. L.; Schwager, S. L.; Redelinghuys, P.; Carmona, A. K.; Ehlers, M. R.; et al. The N-domain of somatic angiotensin-converting enzyme negatively regulates ectodomain shedding and catalytic activity. Biochem. J. 2005, 389, 739-744.
38. Santhamma, K. R.; Sadhukhan, R.; Kinter, M.; Chattopadhyay, S.; McCue, B.; et al. Role of tyrosine phosphorylation in the regulation of cleavage secretion of angiotensinconverting enzyme. J. Biol. Chem. 2004, 279, 40227-40236.
39. Kohlstedt, K.; Shoghi, F.; Muller-Esterl, W.; Busse, R.; Fleming, I. CK2 phosphorylates the angiotensin-converting enzyme and regulates its retention in the endothelial cell plasma membrane. Circ. Res. 2002, 91, 749-756.
40. Fleming, I.; Kohlstedt, K.; Busse, R. The tissue renin-angiotensin system and intracellular signalling. Curr. Opin. Nephrol. Hypertens. 2006, 15, 8-13.
41. Hooper, N.M. Angiotensin converting enzyme: implications from molecular biology for its physiological functions. Int. J. Biochem. 1991, 23, 641-647.
42. Wei, L.; Alhenc-Gelas, F.; Soubrier, F.; Michaud, A.; Corvol, P.; et al. Expression and characterization of recombinant human angiotensin I-converting enzyme. Evidence for a C-terminal transmembrane anchor and for a proteolytic processing of the secreted recombinant and plasma enzymes. J. Biol. Chem. 1991, 266, 5540-5546.
43. Studdy, P. R.; Lapworth, R.; Bird, R. Angiotensin-converting enzyme and its clinical significance: a review. J. Clin. Pathol. 1983, 36, 938-947.
44. Erdos, E. G.; Skidgel, R. A. The angiotensin I-converting enzyme. Lab. Invest. 1987, 56, 345-348.
45. Oosterga, M.; Voors, A. A.; de Kam, P. J.; Schunkert, H.; Pinto, Y. M.; et al. Plasma angiotensin-converting enzyme activity and left ventricular dilation after myocardial infarction. Circulation 1997, 95, 2607-2609.
46. Altstein, M.; Dudai,Y.;Vogel, Z. Angiotensin-converting enzyme associated with Torpedo california electric organ membranes. J. Neurosci. Res. 1987, 18, 333-340.
47. Turner, A. J.; Hryszko, J.; Hooper, N. M.; Dowdall, M. J. Purification and characterization of a peptidyl dipeptidase resembling angiotensin converting enzyme from the electric organ of Torpedo marmorata. J. Neurochem. 1987, 48, 910-916.
48. Gunes, H. V.; Ata, N.; Degirmenci, I.; Basaran, A.; Timuralp, B.; et al. Frequency of angiotensin-converting enzyme gene polymorphism in Turkish hypertensive patients. Int. J. Clin. Pract. 2004, 58, 838-843.
49. Okawara, Y.; Kobayashi, H. Enhancement of water intake by captopril (SQ14225), an angiotensin I-converting enzyme inhibitor, in the goldfish, Carassius auratus. Gen. Comp. Endocrinol. 1988, 69, 114-118.
50. Esther,C. R., Jr.; Thomas, K. E.; Bernstein, K. E. Chicken lacks the testis specific isozyme of angiotensin converting enzyme found in mammals. Biochem. Biophys. Res. Commun. 1994, 205, 1916-1921.
51. Lamango, N.; Isaac, R. E. Identification of an ACE-like peptidyl dipeptidase activity in the housefly, Musca domestica. Biochem. Soc. Trans. 1993, 21 (Part 3), 245S.
52. Cornell, M. J.;Williams, T. A.; Lamango, N. S.; Coates, D.; Corvol, P.; et al. Cloning and expression of an evolutionary conserved single-domain angiotensin converting enzyme from Drosophila melanogaster. J. Biol. Chem. 1995, 270, 13613-13619.
53. Isaac, R. E. Peptidyl-dipeptidaseA(invertebrate). Handbook of Proteolytic Enzymes, 2nd ed.; Academic Press: London, 2004; pp 347-349.
54. Kim, H. M.; Shin, D. R.; Yoo, O. J.; Lee, H.; Lee, J. O. Crystal structure of Drosophila angiotensin I-converting enzyme bound to captopril and lisinopril. FEBS Lett. 2003, 538, 65-70.
55. Houard, X.; Williams, T. A.; Michaud, A.; Dani, P.; Isaac, R. E.; et al. The Drosophila melanogaster-related angiotensin-I-converting enzymes Acer and Ance: distinct enzymic characteristics and alternative expression during pupal development. Eur. J. Biochem. 1998, 257, 599-606.
56. Tipnis, S. R.; Hooper, N. M.; Hyde, R.; Karran, E.; Christie, G.; et al. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captoprilinsensitive carboxypeptidase. J. Biol. Chem. 2000, 275, 33238-33243.
57. Donoghue, M.; Hsieh, F.; Baronas, E.; Godbout, K.; Gosselin, M.; et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res. 2000, 87, E1-E9.
58. Guy, J. L.; Lambert, D. W.; Warner, F. J.; Hooper, N. M.; Turner, A. J. Membraneassociated zinc peptidase families: comparing ACE and ACE2. Biochim. Biophys. Acta 2005, 1751, 2-8.
59. Chou, C. F.; Loh, C. B.; Foo, Y. K.; Shen, S.; Fielding, B. C.; et al. ACE2 orthologues in non-mammalian vertebrates (Danio, Gallus, Fugu, Tetraodon and Xenopus). Gene 2006, 377, 46-55.
60. Ferreira, A. J.; Raizada, M. K. Are we poised to target ACE2 for the next generation of antihypertensives? J. Mol. Med. 2008, 86, 685-690.
61. Turner, A. J.; Hooper, N.M. The angiotensin-converting enzyme gene family: genomics and pharmacology. Trends Pharmacol. Sci. 2002, 23, 177-183.
62. Rella, M.; Elliot, J. L.; Revett, T. J.; Lanfear, J.; Phelan, A.; et al. Identification and characterisation of the angiotensin converting enzyme-3 (ACE3) gene: a novel mammalian homologue of ACE. BMC Genomics 2007, 8, 194.
63. Riviere, G.; Michaud, A.; Corradi, H. R.; Sturrock, E. D.; Ravi Acharya, K.; et al. Characterization of the first angiotensin-converting like enzyme in bacteria: ancestor ACE is already active. Gene 2007, 399, 81-90.
64. Shen, X. Z.; Xiao, H. D.; Li, P.; Lin, C. X.; Billet, S.; et al. New insights into the role of angiotensin-converting enzyme obtained from the analysis of genetically modified mice. J. Mol. Med. 2008, 86, 679-684.
65. Shen, X. Z.; Xiao, H. D.; Li, P.; Lin, C. X.; Fuchs, S.; et al. Tissue specific expression of angiotensin converting enzyme: a newway to study an old friend. Int. Immunopharmacol. 2008, 8, 171-176.
66. Fuchs, S.; Xiao, H. D.; Hubert, C.; Michaud, A.; Campbell, D. J.; et al. Angiotensinconverting enzyme C-terminal catalytic domain is the main site of angiotensin I cleavage in vivo. Hypertension 2008, 51, 267-274.
67. Natesh, R.; Schwager, S. L.; Sturrock, E. D.; Acharya, K. R. Crystal structure of the human angiotensin-converting enzyme-lisinopril complex. Nature 2003, 421, 551-554.
68. Yu, X. C.; Sturrock, E. D.; Wu, Z.; Biemann, K.; Ehlers, M. R.; et al. Identification of N-linked glycosylation sites in human testis angiotensin-converting enzyme and expression of an active deglycosylated form. J. Biol. Chem. 1997, 272, 3511-3519.
69. Gordon, K.; Redelinghuys, P.; Schwager, S. L.; Ehlers, M. R.; Papageorgiou, A. C.; et al. Deglycosylation, processing and crystallization of human testis angiotensin-converting enzyme. Biochem. J. 2003, 371, 437-442.
70. Williams, T. A.; Michaud, A.; Houard, X.; Chauvet, M. T.; Soubrier, F.; et al. Drosophila melanogaster angiotensin I-converting enzyme expressed in Pichia pastoris resembles the C-domain of the mammalian homologue and does not require glycosylation for secretion and enzymic activity. Biochem. J. 1996, 318 (Part 1), 125-131.
71. Sturrock, E. D.; Natesh, R.; van Rooyen, J. M.; Acharya, K. R. Structure of angiotensin I-converting enzyme. Cell Mol. Life Sci. 2004, 61, 2677-2686.
72. Holm, L.; Sander, C. Protein folds and families: sequence and structure alignments. Nucleic Acids Res. 1999, 27, 244-247.
73. Comellas-Bigler, M.; Lang, R.; Bode, W.; Maskos, K. Crystal structure of the E. coli dipeptidyl carboxypeptidase Dcp: further indication of a ligand-dependent hinge movement mechanism. J. Mol. Biol. 2005, 349, 99-112.
74. Ray, K.; Hines, C. S.; Coll-Rodriguez, J.; Rodgers, D. W. Crystal structure of human thimet oligopeptidase provides insight into substrate recognition, regulation, and localization. J. Biol. Chem. 2004, 279, 20480-20489.
75. Corradi, H. R.; Schwager, S. L.;Nchinda, A. T.; Sturrock, E.D.; Acharya, K. R. Crystal structure of the N-domain of human somatic angiotensin I-converting enzyme provides a structural basis for domain-specific inhibitor design. J. Mol. Biol. 2006, 357, 964-974.
76. Natesh, R.; Schwager, S. L.; Evans, H. R.; Sturrock, E. D.; Acharya, K. R. Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme. Biochemistry 2004, 43, 8718-8724.
77. Corradi, H. R.; Chitapi, I.; Sewell, B. T.; Georgiadis, D.; Dive, V.; et al. The structure of testis angiotensin-converting enzyme in complex with the C-domain-specific inhibitor RXPA380. Biochemistry 2007, 46, 5473-5478.
78. Naqvi, N.; Liu, K.; Graham, R. M.; Husain, A. Molecular basis of exopeptidase activity in the C-terminal domain of human angiotensin I-converting enzyme: insights into the origins of its exopeptidase activity. J. Biol. Chem. 2005, 280, 6669-6675.
79. Fernandez,M.;Liu, X.;Wouters, M.A.;Heyberger, S.;Husain, A. AngiotensinI-converting enzyme transition state stabilization by HIS1089: evidence for a catalytic mechanism distinct from other gluzincin metalloproteinases. J. Biol. Chem. 2001, 276, 4998-5004.
80. Towler, P.; Staker, B.; Prasad, S. G.; Menon, S.; Tang, J.; et al. ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis. J. Biol. Chem. 2004, 279, 17996-18007.
81. Holland, D. R.; Tronrud, D. E.; Pley, H.W.; Flaherty, K. M.; Stark,W.; et al. Structural comparison suggests that thermolysin and related neutral proteases undergo hingebending motion during catalysis. Biochemistry 1992, 31, 11310-11316.
82. Watermeyer, J. M.; Sewell, B. T.; Schwager, S. L.; Natesh, R.; Corradi, H. R.; et al. Structure of testis ACE glycosylation mutants and evidence for conserved domain movement. Biochemistry 2006, 45, 12654-12663.
83. Bunning, P.; Holmquist, B.; Riordan, J. F. Substrate specificity and kinetic characteristics of angiotensin converting enzyme. Biochemistry 1983, 22, 103-110.
84. Andujar-Sanchez, M.; Jara-Perez, V.; Camara-Artigas, A. Thermodynamic determination of the binding constants of angiotensin-converting enzyme inhibitors by a displacement method. FEBS Lett. 2007, 581, 3449-3454.
85. Liu, X.; Fernandez, M.;Wouters, M. A.; Heyberger, S.; Husain, A. Arg(1098) is critical for the chloride dependence of human angiotensin I-converting enzyme C-domain catalytic activity. J. Biol. Chem. 2001, 276, 33518-33525.
86. Skirgello, O. E.; Binevski, P. V.; Pozdnev, V. F.; Kost, O. A. Kinetic probes for interdomain co-operation in human somatic angiotensin-converting enzyme. Biochem. J. 2005, 391, 641-647.
87. Sturrock, E. D.; Danilov, S. M.; Riordan, J. F. Limited proteolysis of human kidney angiotensin-converting enzyme and generation of catalytically active N- and C-terminal domains. Biochem. Biophys. Res. Commun. 1997, 236, 16-19.
88. Olden, K.; Pratt, R. M.; Jaworski, C.; Yamada, K. M. Evidence for role of glycoprotein carbohydrates in membrane transport: specific inhibition by tunicamycin. Proc. Natl. Acad. Sci. USA 1979, 76, 791-795.
89. Ripka, J. E.; Ryan, J. W.; Valido, F. A.; Chung, A. Y.; Peterson, C. M.; et al. N-glycosylation of forms of angiotensin converting enzyme from four mammalian species. Biochem. Biophys. Res. Commun. 1993, 196, 503-508.
90. Ehlers, M. R.; Chen, Y. N.; Riordan, J. F. The unique N-terminal sequence of testis angiotensin-converting enzyme is heavily O-glycosylated and unessential for activity or stability. Biochem. Biophys. Res. Commun. 1992, 183, 199-205.
91. Baudin, B.; Alves, N.; Pilon, A.; Beneteau-Burnat, B.; Giboudeau, J. Structural and biological roles of glycosylations in pulmonary angiotensin I-converting enzyme. Glycobiology 1997, 7, 565-570.
92. Kasturi, S.; Jabbar, M. A.; Sen, G. C.; Sen, I. Role of glycosylation in the biosynthesis and activity of rabbit testicular angiotensin-converting enzyme. Biochemistry 1994, 33, 6228-6234.
93. Sadhukhan, R.; Sen, I. Different glycosylation requirements for the synthesis of enzymatically active angiotensin-converting enzyme in mammalian cells and yeast. J. Biol. Chem. 1996, 271, 6429-6434.
94. Cascieri, M. A.; Bull, H. G.; Mumford, R. A.; Patchett, A. A.; Thornberry, N. A.; et al. Carboxyl-terminal tripeptidyl hydrolysis of substance P by purified rabbit lung angiotensin- converting enzyme and the potentiation of substance P activity in vivo by captopril and MK-422. Mol. Pharmacol. 1984, 25, 287-293.
95. Dubreuil, P.; Fulcrand, P.; Rodriguez, M.; Fulcrand, H.; Laur, J.; et al. Novel activity of angiotensin-converting enzyme. Hydrolysis of cholecystokinin and gastrin analogues with release of the amidated C-terminal dipeptide. Biochem. J. 1989, 262, 125-130.
96. Skidgel, R. A.; Erdos, E. G. Novel activity of human angiotensin I converting enzyme: release of the NH2- and COOH-terminal tripeptides from the luteinizing hormonereleasing hormone. Proc. Natl. Acad. Sci. USA 1985, 82, 1025-1029.
97. Skidgel, R. A.; Engelbrecht, S.; Johnson, A. R.; Erdos, E. G. Hydrolysis of substance P and neurotensin by converting enzyme and neutral endopeptidase. Peptides 1984, 5, 769-776.
98. Yokosawa, H.; Endo, S.; Ohgaki, Y.; Maeyama, J.; Ishii, S. Hydrolysis of substance P and its analogs by angiotensin-converting enzyme from rat lung. Characterization of endopeptidase activity of the enzyme. J. Biochem. 1985, 98, 1293-1299.
99. Jaspard, E.; Wei, L.; Alhenc-Gelas, F. Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides. J. Biol. Chem. 1993, 268, 9496-9503.
100. Rousseau, A.; Michaud, A.; Chauvet, M. T.; Lenfant, M.; Corvol, P. The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme. J. Biol. Chem. 1995, 270, 3656-3661.
101. Wei, L.; Clauser, E.; Alhenc-Gelas, F.; Corvol, P. The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors. J. Biol. Chem. 1992, 267, 13398-13405.
102. Vazeux, G.; Cotton, J.; Cuniasse, P.; Dive, V. Potency and selectivity of RXP407 on human, rat, and mouse angiotensin-converting enzyme. Biochem. Pharmacol. 2001, 61, 835-841.
103. Georgiadis, D.; Cuniasse, P.; Cotton, J.;Yiotakis, A.; Dive, V. Structural determinants of RXPA380, a potent and highly selective inhibitor of the angiotensin-converting enzyme C-domain. Biochemistry 2004, 43, 8048-8054.
104. Andujar-Sanchez, M.; Camara-Artigas, A.; Jara-Perez, V. A calorimetric study of the binding of lisinopril, enalaprilat and captopril to angiotensin-converting enzyme. Biophys. Chem. 2004, 111, 183-189.
105. Binevski, P. V.; Sizova, E. A.; Pozdnev, V. F.; Kost, O. A. Evidence for the negative cooperativity of the two active sites within bovine somatic angiotensin-converting enzyme. FEBS Lett. 2003, 550, 84-88.
106. Rawlings, N. D.; Morton, F. R.; Kok, C. Y.; Kong, J.; Barrett, A. J. MEROPS: the peptidase database. Nucleic Acids Res. 2008, 36, D320-D325.
107. Holden, H. M.; Matthews, B. W. The binding of L-valyl-L-tryptophan to crystalline thermolysin illustrates the mode of interaction of a product of peptide hydrolysis. J. Biol. Chem. 1988, 263, 3256-3260.
108. Pelmenschikov, V.; Blomberg, M. R.; Siegbahn, P. E. A theoretical study of the mechanism for peptide hydrolysis by thermolysin. J. Biol. Inorg. Chem. 2002, 7, 284-298.
109. Tzakos, A. G.; Galanis, A. S.; Spyroulias, G. A.; Cordopatis, P.; Manessi-Zoupa, E.; et al. Structure-function discrimination of the N- and C-catalytic domains of human angiotensin- converting enzyme: implications for Cl-activation and peptide hydrolysis mechanisms. Protein Eng. 2003, 16, 993-1003.
110. Dion, N.; Le Moual, H.; Crine, P.; Boileau, G. Kinetic evidence that His-711 of neutral endopeptidase 24.11 is involved in stabilization of the transition state. FEBS Lett. 1993, 318, 301-304.
111. Arnett, D. K.; Claas, S. A.; Glasser, S. P. Pharmacogenetics of antihypertensive treatment. Vascul. Pharmacol. 2006, 44, 107-118.
112. Chappell, M. C.; Modrall, J. G.; Diz, D. I.; Ferrario, C. M. Novel aspects of the renal renin-angiotensin system: angiotensin-(1-7), ACE2 and blood pressure regulation. Contrib. Nephrol. 2004, 143, 77-89.
113. Kurdi, M.; De Mello, W. C.; Booz, G. W. Working outside the system: an update on the unconventional behavior of the renin-angiotensin system components. Int. J. Biochem. Cell Biol. 2005, 37, 1357-1367.
114. Carey, R. M.; Siragy, H. M. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr. Rev. 2003, 24, 261-271.
115. Cushman, D.W. C.;Hong, S.; Sabo, E. F.;Ondetti,M. A. Angiotensin Converting Enzyme Inhibitors: Evolution of aNew Class of Antihypertensive Drugs; Urban&Schwarzenberg: Baltimore, 1981; pp 3-25.
116. Schechter, I.; Berger, A. On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 1967, 27, 157-162.
117. Salvetti, A. Newer ACE inhibitors. A look at the future. Drugs 1990, 40, 800-828.
118. Utsunomiya, K.; Ikeda, Y.; Alacepril Study Group. Beneficial effect of alacepril, a new angiotensin-converting enzyme inhibitor on albuminuria and glycemic state: an open multicenter trial. J. Diabet. Complications 1991, 5, 165-166.
119. Sakai, K.; Aono, J.; Shiraki, Y.; Hinohara, Y.; Akamatsu, A.; et al. MC-838 (altiopril calcium): a novel orally active angiotensin converting enzyme inhibitor. Tohoku J. Exp. Med. 1987, 152, 363-374.
120. Unger, T.; Yukimura, T.; Marin-Grez, M.; Lang, R. E.; Rascher,W.; et al. SA446, a new orally active converting enzyme inhibitor: antihypertensive action and comparison with captopril in stroke-prone spontaneously hypersensitive rats. Eur. J. Pharmacol. 1982, 78, 411-420.
121. Borghi, C.; Bacchelli, S.; Degli Esposti, D.; Ambrosioni, E. A reviewof the angiotensinconverting enzyme inhibitor, zofenopril, in the treatment of cardiovascular diseases. Expert Opin. Pharmacother. 2004, 5, 1965-1977.
122. DiBianco, R. Adverse reactions with angiotensin converting enzyme (ACE) inhibitors. Med. Toxicol. 1986, 1, 122-141.
123. Furness, P. N.; Goodfield, M. J.; MacLennan, K. A.; Stevens, A.; Millard, L. G. Severe cutaneous reactions to captopril and enalapril; histological study and comparison with early mycosis fungoides. J. Clin. Pathol. 1986, 39, 902-907.
124. Frohlich, E. D.; Cooper, R. A.; Lewis, E. J. Review of the overall experience of captopril in hypertension. Arch. Intern. Med. 1984, 144, 1441-1444.
125. Brown, N. J.; Vaughan, D. E. Angiotensin-converting enzyme inhibitors. Circulation 1998, 97, 1411-1420.
126. Voors, A.; Herre Kingma, J.; van Gilst, W. Drug differences between ACE-inhibitors in experimental settings and clinical practice. J. Cardiovasc. Risk 1995, 2, 413-422.
127. Pi, X. J.; Chen, X. Captopril and ramiprilat protect against free radical injury in isolated working rat hearts. J. Mol. Cell Cardiol. 1989, 21, 1261-1271.
128. Przyklenk, K.; Kloner, R. A. Angiotensin converting enzyme inhibitors improve contractile function of stunned myocardium by different mechanisms of action. Am. Heart J. 1991, 121, 1319-1330.
129. van Gilst, W. H.; de Graeff, P. A.; de Leeuw, M. J.; Scholtens, E.; Wesseling, H. Converting enzyme inhibitors and the role of the sulfhydryl group in the potentiation of exo- and endogenous nitrovasodilators. J. Cardiovasc. Pharmacol. 1991, 18, 429-436.
130. Ulm, E. H. Enalapril maleate (MK-421), a potent, nonsulfhydryl angiotensin-converting enzyme inhibitor: absorption, disposition, and metabolism in man. Drug Metab. Rev. 1983, 14, 99-110.
131. Kaplan, H. R.; Cohen, D. M.; Essenburg, A. D.; Major, T. C.; Mertz, T. E.; et al. CI-906 and CI-907: new orally active nonsulfhydryl angiotensin-converting enzyme inhibitors. Fed. Proc. 1984, 43, 1326-1329.
132. Ulm, E. H.; Hichens, M.; Gomez, H. J.;Till, A. E.; Hand, E.; et al. Enalapril maleate and a lysine analogue (MK-521): disposition in man. Br. J. Clin. Pharmacol. 1982, 14, 357-362.
133. Ball, S. G.; Robertson, J. I. Clinical pharmacology of ramipril. Am. J. Cardiol. 1987, 59, 23D-27D.
134. Williams, P. E.; Brown, A. N.; Rajaguru, S.; Francis, R. J.; Walters, G. E.; et al. The pharmacokinetics and bioavailability of cilazapril in normal man. Br. J. Clin. Pharmacol. 1989, 27 (Suppl. 2), 181S-188S.
135. Guay, D. R. Trandolapril: a newer angiotensin-converting enzyme inhibitor. Clin. Ther. 2003, 25, 713-775.
136. Kubo, M.; Kato, J.; Ochiai, T.; Ishida, R. Pharmacological studies on (4S)-1-methyl-3-[(2S)-2-[N-((1S)-1-ethoxycarbonyl-3-phenylpropyl)amino] propionyl]-2-oxo-imidazolidine-4-carboxylic acid hydrochloride (TA-6366), a newACE inhibitor: I.ACE inhibitory and anti-hypertensive activities. Jpn. J. Pharmacol. 1990, 53, 201-210.
137. Sybertz, E. J.;Watkins, R.W.; Ahn, H. S.; Baum, T.; La Rocca, P.; et al. Pharmacologic, metabolic, and toxicologic profile of spirapril (SCH 33844), a newangiotensin converting inhibitor. J. Cardiovasc. Pharmacol. 1987, 10 (Suppl. 7), S105-S108.
138. Kaiser, G.; Ackermann, R.; Sioufi, A. Pharmacokinetics of a newangiotensin-converting enzyme inhibitor, benazepril hydrochloride, in special populations. Am. Heart J. 1989, 117, 746-751.
139. Klutchko, S.; Blankley, C. J.; Fleming, R. W.; Hinkley, J. M.; Werner, A. E.; et al. Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types. J. Med. Chem. 1986, 29, 1953-1961.
140. Razzetti, R.; Acerbi, D. Pharmacokinetic and pharmacologic properties of delapril, a lipophilic nonsulfhydryl angiotensin-converting enzyme inhibitor. Am. J. Cardiol. 1995, 75, 7F-12F.
141. Parker, E.; Aarons, L.; Rowland, M.; Resplandy, G. The pharmacokinetics of perindoprilat in normal volunteers and patients: influence of age and disease state. Eur. J. Pharm. Sci. 2005, 26, 104-113.
142. Graf, P.; Frueh, F.; Schmid, K. Determination of the angiotensin converting enzyme inhibitor benazeprilat in plasma and urine by an enzymic method. J. Chromatogr. 1988, 425, 353-361.
143. Azizi, M.; Massien, C.; Michaud, A.; Corvol, P. In vitro and in vivo inhibition of the 2 active sites of ACE by omapatrilat, a vasopeptidase inhibitor. Hypertension 2000, 35, 1226-1231.
144. Robl, J. A.; Sun, C. Q.; Stevenson, J.; Ryono, D. E.; Simpkins, L. M.; et al. Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J. Med. Chem. 1997, 40, 1570-1577.
145. Singhvi, S. M.; Duchin, K. L.; Morrison, R. A.; Willard, D. A.; Everett, D. W.; et al. Disposition of fosinopril sodiumin healthy subjects. Br. J. Clin.Pharmacol. 1988, 25, 9-15.
146. Dive,V.; Cotton, J.;Yiotakis, A.; Michaud, A.;Vassiliou, S.; et al. RXP407, a phosphinic peptide is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites. Proc. Natl. Acad. Sci. USA 1999, 96, 4330-4335.
147. Georgiadis, D.; Beau, F.; Czarny, B.; Cotton, J.; Yiotakis, A.; et al. Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors. Circ. Res. 2003, 93, 148-154.
148. Subissi, A.; Criscuoli, M.; Sardelli, G.; Guelfi, M.; Giachetti, A. Pharmacology of idrapril: a new class of angiotensin converting enzyme inhibitors. J. Cardiovasc. Pharmacol. 1992, 20, 139-146.
149. Turbanti, L.; Cerbai, G.; Di Bugno, C.; Giorgi, R.; Garzelli, G.; et al. 1,2-Cyclomethylenecarboxylic monoamide hydroxamic derivatives. A novel class of non-amino acid angiotensin converting enzyme inhibitors. J. Med. Chem. 1993, 36, 699-707.
150. Deddish, P. A.; Marcic, B.; Jackman, H. L.; Wang, H. Z.; Skidgel, R. A.; et al. Ndomain- specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotensin-(1-7) and keto-ACE. Hypertension 1998, 31, 912-917.
151. Nchinda, A. T.; Chibale, K.; Redelinghuys, P.; Sturrock, E. D. Synthesis of novel keto-ACE analogues as domain-selective angiotensin I-converting enzyme inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 4612-4615.
152. Redelinghuys, P.; Nchinda, A. T.; Chibale, K.; Sturrock, E. D. Novel ketomethylene inhibitors of angiotensin I-converting enzyme (ACE): inhibition and molecular modelling. Biol. Chem. 2006, 387, 461-466.
153. Meyer, R. F.; Nicolaides, E. D.; Tinney, F. J.; Lunney, E. A.; Holmes, A.; et al. Novel synthesis of (S)-1-[5-(benzoylamino)-1,4-dioxo-6-phenylhexyl]-L-proline and analogues: potent angiotensin converting enzyme inhibitors. J. Med. Chem. 1981, 24, 964-969.
154. Galanis, A. S.; Spyroulias, G. A.; Pierattelli, R.; Tzakos, A.; Troganis, A.; et al. Zinc binding in peptide models of angiotensin-I converting enzyme active sites studied through 1H-NMR and chemical shift perturbation mapping. Biopolymers 2003, 69, 244-252.
155. Tzakos, A. G.; Naqvi, N.; Comporozos, K.; Pierattelli, R.; Theodorou, V.; et al. The molecular basis for the selection of captopril cis and trans conformations by angiotensin I converting enzyme. Bioorg. Med. Chem. Lett. 2006, 16, 5084-5087.
156. Nchinda, A. T.; Chibale, K.; Redelinghuys, P.; Sturrock, E. D. Synthesis and molecular modeling of a lisinopril-tryptophan analogue inhibitor of angiotensin I-converting enzyme. Bioorg. Med. Chem. Lett. 2006, 16, 4616-4619.
157. Tissot, A. C.; Maurer, P.; Nussberger, J.; Sabat, R.; Pfister, T.; et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a doubleblind, randomised, placebo-controlled phase IIa study. Lancet 2008, 371, 821-827.
158. Michaud, A.; Williams, T. A.; Chauvet, M. T.; Corvol, P. Substrate dependence of angiotensin I-converting enzyme inhibition: captopril displays a partial selectivity for inhibition of N-acetyl-seryl-aspartyl-lysyl-proline hydrolysis compared with that of angiotensin I. Mol. Pharmacol. 1997, 51, 1070-1076.